Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bupivacaine extended release - Pacira BioSciences

Next Previous
X
Search
Drug Profile

Bupivacaine extended release - Pacira BioSciences

Alternative Names: Bupivacaine extended-release - Pacira BioSciences; Bupivacaine extended-release liposome injection; Bupivacaine liposome extended-release injectable suspension; Bupivacaine liposome injectable suspension; DepoBupivacaine; Exparel; SKY-0402

Latest Information Update: 09 Dec 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator SkyePharma Inc
  • Developer Nuance Biotech; Pacira BioSciences; Pacira Pharmaceuticals
  • Class Analgesics; Anilides; Anti-inflammatories; Local anaesthetics; Non-opioid analgesics; Pipecolic acids; Piperidines; Small molecules
  • Mechanism of Action Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Anaesthesia; Postoperative pain
  • Phase III Dental pain
  • No development reported Musculoskeletal pain; Pain

Most Recent Events

  • 03 Dec 2024 Pacira BioSciences is advancing a lawsuit against eVenus Pharmaceutical Laboratories, Jiangsu Hengrui, and Fresenius for infringement of the ‘574 patent" in the U.S. District Court for the District of New Jersey, before December 2024
  • 03 Dec 2024 Pacira BioSciences receives a “Manufacturing of Bupivacaine Multivesicular Liposomes” protects the chemical composition of EXPAREL® (bupivacaine liposome injectable suspension) from the US PTO
  • 03 Dec 2024 Pacira BioSciences receives the ‘024 patent and the ‘890 patent related to EXPAREL® (bupivacaine liposome injectable suspension) from the US PTO before December 2024

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top